ArticleFrontiers in oncology2020

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.

Huabin Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.